Medicare AdvantageCoverageLow impact
MA08.034d, Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme®, Elaprase®, Vimizim®, Naglazyme®, Mepsevii™, etc.)
Independence Blue Cross·Endocrinology, Pediatrics, Internal Medicine +1 more·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.034d for enzyme replacement therapy for mucopolysaccharidosis has been reissued with an effective date of November 26, 2025. This policy covers specialty medications like Aldurazyme, Elaprase, Vimizim, Naglazyme, and Mepsevii used to treat rare genetic disorders.
Action Required
By November 26, 2025: Billing team should review the updated policy MA08.034d on the IBX website to understand any changes to coverage criteria or prior authorization requirements for enzyme replacement therapy medications used in mucopolysaccharidosis treatment. Update billing procedures and staff training as needed based on policy details.